NCT05507996

Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

An Investigator-initiated Trial Evaluating the Efficacy and Safety of Recombinant Adeno-associated Virus Administration in Patients With Menkes Syndrome

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Kunming Hope of Health Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

It is a single-center, open, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of recombinant adeno-associated virus administration for patients with Menkes syndrome.

Detailed description

Who can participate? Patients with Menkes syndrome were diagnosed by combining clinical and genetic diagnoses. How to conduct this study? In this study, the constructed recombinant adeno-associated virus preparation will be delivered to patients with Menkes syndrome. After administration, close follow-up will be conducted for at least three months, followed by regular follow-up until at least the 12th month. The efficacy and safety of treatment will be observed and evaluated. After the completion of the study, participants will decide whether to participate in the long-term follow-up program for five years. What are the possible benefits and risks of participating? Benefits: This study may prolong the life span and improve the prognosis of Menkes syndrome subjects. The information obtained from this study will help determine what treatment may be safe and effective for other subjects with similar conditions. Risks: Subjects may have adverse reactions to the treatment. These adverse reactions may include abnormal liver injury, fever, thrombocytopenia, thrombotic microangiopathy, and possibly others. Where is the study run? Kunming Hope of Health Hospital.

Conditions

• Menkes Syndrome

Interventions

Type	Name	Description
DRUG	Recombinant adeno-associated virus administration	The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.

Timeline

• Start date: 2022-08-18
• Primary completion: 2022-11-23
• Completion: 2022-11-23
• First posted: 2022-08-19
• Last updated: 2022-11-30

Locations

1 site across 1 country: China